Literature DB >> 1353743

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.

D Rachmilewitz1, F Karmeli, L W Schwartz, P L Simon.   

Abstract

The effect of 5-ASA and 4-ASA, drugs used for the treatment of inflammatory bowel disease, on modulation of experimental colitis and on colonic generation of interleukin-1 was evaluated. Three weeks of treatment with 5-ASA or 4-ASA (50 micrograms/kg) and one week of treatment with 5-ASA significantly decreased colonic interleukin-1 generation and the extent and severity of inflammation in a rat model of colitis induced by trinitrobenzene sulphonic acid. Colonic biopsies were obtained from patients with active ulcerative colitis and organ cultured 24 hours in the absence or presence of the following drugs: sulphasalazine, sulphapyridine, 5-ASA and 4-ASA (25-100 micrograms/ml). Interleukin-1 content in tissue cultured in the presence of 5-ASA (100 micrograms/ml) was two-thirds of its content in tissue cultured in drug free medium and its release into the medium was decreased by 50%. Sulphasalazine 50 micrograms/ml significantly decreased by 33% the tissue content but did not affect interleukin-1 release and a higher dose was not more effective. Sulphapyridine and 4-ASA in doses up to 100 micrograms/ml did not affect either interleukin-1 colonic content or its release into the culture medium. We conclude that pharmacological suppression of colonic interleukin-1 generation may be one, although not the sole mechanism to explain the therapeutic efficacy of 5-ASA in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353743      PMCID: PMC1379406          DOI: 10.1136/gut.33.7.929

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

2.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

Authors:  R Eliakim; F Karmeli; E Razin; D Rachmilewitz
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

3.  Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production.

Authors:  D S Snyder; E R Unanue
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

4.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

5.  Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.

Authors:  F Cominelli; C C Nast; B D Clark; R Schindler; R Lierena; V E Eysselein; R C Thompson; C A Dinarello
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

Authors:  Y R Mahida; C E Lamming; A Gallagher; A B Hawthorne; C J Hawkey
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

7.  Purification and characterization of human recombinant interleukin-1 beta.

Authors:  C A Meyers; K O Johanson; L M Miles; P J McDevitt; P L Simon; R L Webb; M J Chen; B P Holskin; J S Lillquist; P R Young
Journal:  J Biol Chem       Date:  1987-08-15       Impact factor: 5.157

8.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

Authors:  P P Bradley; D A Priebat; R D Christensen; G Rothstein
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

9.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

10.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

View more
  11 in total

1.  Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis.

Authors:  Hua-Ying Fan; Zi-Liang Zhang; Ke Liu; Ming-Yan Yang; Wei-Hong Lv; Xin Che; Hui Xu; Wei-Wei Song
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.

Authors:  Antonio Tursi; Raymond E Joseph; Paul Streck
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

5.  Design, Synthesis, and Testing of a Molecular Truck for Colonic Delivery of 5-Aminosalicylic Acid.

Authors:  Suryakiran Navath; Venkataramanarao Rao; Rita-Marie T Woodford; Monica T Midura-Kiela; Ali M Ahad; Ramesh Alleti; Pawel R Kiela; Eugene A Mash
Journal:  ACS Med Chem Lett       Date:  2012-08-01       Impact factor: 4.345

6.  Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.

Authors:  J Gálvez; M Garrido; M Merlos; M I Torres; A Zarzuelo
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 7.  Mesalazine in inflammatory bowel disease: a trendy topic once again?

Authors:  Marietta Iacucci; Shanika de Silva; Sabrata Ghosh
Journal:  Can J Gastroenterol       Date:  2010-02       Impact factor: 3.522

Review 8.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Authors:  Glen A Doherty; Mark A Peppercorn
Journal:  Clin Exp Gastroenterol       Date:  2009-12-08

Review 10.  Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.

Authors:  F Scaldaferri; V Petito; L Lopetuso; G Bruno; V Gerardi; G Ianiro; A Sgambato; A Gasbarrini; G Cammarota
Journal:  Mediators Inflamm       Date:  2013-05-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.